Fibroblast Growth Factor 21: A Novel Metabolic Regulator With Potential Therapeutic Properties in Obesity/Type 2 Diabetes Mellitus

被引：62
作者：
Dostalova, I. [1 ]
Haluzikova, D. [1 ,2 ,3 ]
Haluzik, M. [1 ]
机构：
[1] Charles Univ Prague, Dept Med 3, Fac Med 1, Nemocnice 1, Prague 12808 2, Czech Republic
[2] Charles Univ Prague, Dept Sports Med, Fac Med 1, Prague, Czech Republic
[3] Charles Univ Prague, Gen Univ Hosp, Prague, Czech Republic
来源：
PHYSIOLOGICAL RESEARCH | 2009年 / 58卷 / 01期
关键词：
Fibroblast growth factor 21; Fasting; Obesity; Type; 2; diabetes; Peroxisome proliferator-activated receptor; Glucose uptake; PPAR-ALPHA; INSULIN-RESISTANCE; BETA-KLOTHO; RECEPTOR; FGF; EXPRESSION; FIBROBLAST-GROWTH-FACTOR-21; SIGNAL; KINASE; IDENTIFICATION;
D O I：
10.33549/physiolres.931610
中图分类号：
Q4 [生理学];
学科分类号：
071003 ;
摘要：
Fibroblast growth factor 21 (FGF21) is a novel metabolic regulator produced primarily by the liver that exerts potent antidiabetic and lipid-lowering effects in animal models of obesity and type 2 diabetes mellitus. This hormone contributes to body weight regulation and is strongly involved in the response to nutritional deprivation and ketogenic state in mice. The principal sites of metabolic actions of FGF21 are adipose tissue, liver and pancreas. Experimental studies have shown marked improvements in diabetes compensation and dyslipidemia after FGF21 administration in diabetic mice and primates. Positive metabolic actions of FGF21 without the presence of apparent side effects make this factor a hot candidate to treat type 2 diabetes and accompanying metabolic diseases. The aim of this review is to summarize the current knowledge about the metabolic effects of FGF21 including some preliminary data on changes of its levels in humans with a special emphasis on its therapeutic potential in type 2 diabetes mellitus.
引用
收藏
页码：1 / 7
页数：7
相关论文
共 43 条
[1]  
Badman MK, 2007, CELL METAB, V5, P426, DOI 10.1016/j.cmet.2007.05.002
[2]  
Carballada R, 2001, DEVELOPMENT, V128, P35
[3]   Circulating FGF-21 levels in normal subjects and in newly diagnose patients with type 2 diabetes Mellitus [J].
Chen, W. -W. ;
Li, L. ;
Yang, G. -Y. ;
Li, K. ;
Qi, X. -Y. ;
Zhu, W. ;
Tang, Y. ;
Liu, H. ;
Boden, G. .
EXPERIMENTAL AND CLINICAL ENDOCRINOLOGY & DIABETES, 2008, 116 (01) :65-68
[4]   WY14,643, a peroxisome proliferator-activated receptor α (PPARα) agonist, improves hepatic and muscle steatosis and reverses insulin resistance in lipoatrophic A-ZIP/F-1 mice [J].
Chou, CJ ;
Haluzik, M ;
Gregory, C ;
Dietz, KR ;
Vinson, C ;
Gavrilova, O ;
Reitman, ML .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2002, 277 (27) :24484-24489
[5]   Phosphorylation of STAT-3 in response to basic fibroblast growth factor occurs through a mechanism involving platelet-activating factor, JAK-2, and Src in human umbilical vein endothelial cells - Evidence for a dual kinase mechanism [J].
Deo, DD ;
Axelrad, TW ;
Robert, EG ;
Marcheselli, V ;
Bazan, NG ;
Hunt, JD .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2002, 277 (24) :21237-21245
[6]   Plasma concentrations of fibroblast growth factors 19 and 21 in patients with anorexia nervosa [J].
Dostalova, Ivana ;
Kavalkova, Petra ;
Haluzikova, Denisa ;
Lacinova, Zdena ;
Mraz, Milos ;
Papezova, Hana ;
Haluzik, Martin .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2008, 93 (09) :3627-3632
[7]   Cellular signaling by fibroblast growth factor receptors [J].
Eswarakumar, VP ;
Lax, I ;
Schlessinger, J .
CYTOKINE & GROWTH FACTOR REVIEWS, 2005, 16 (02) :139-149
[8]   Molecular insights into the klotho-dependent, endocrine mode of action of fibroblast growth factor 19 subfamily members [J].
Goetz, Regina ;
Beenken, Andrew ;
Ibrahimi, Omar A. ;
Kalinina, Juliya ;
Olsen, Shaun K. ;
Eliseenkova, Anna V. ;
Xu, ChongFeng ;
Neubert, Thomas A. ;
Zhang, Fuming ;
Linhardt, Robert J. ;
Yu, Xijie ;
White, Kenneth E. ;
Inagaki, Takeshi ;
Kliewer, Steven A. ;
Yamamoto, Masaya ;
Kurosu, Hiroshi ;
Ogawa, Yasushi ;
Kuro-o, Makoto ;
Lanske, Beate ;
Razzaque, Mohammed S. ;
Mohammadi, Moosa .
MOLECULAR AND CELLULAR BIOLOGY, 2007, 27 (09) :3417-3428
[9]   Peroxisome proliferator-activated receptor α activators improve insulin sensitivity and reduce adiposity [J].
Guerre-Millo, M ;
Gervois, P ;
Raspé, E ;
Madsen, L ;
Poulain, P ;
Derudas, B ;
Herbert, JM ;
Winegar, DA ;
Willson, TM ;
Fruchart, JC ;
Berge, RK ;
Staels, B .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2000, 275 (22) :16638-16642
[10]   Adiponectin and its role in the obesity-induced insulin resistance and related complications [J].
Haluzík, M ;
Parízková, J ;
Haluzík, MM .
PHYSIOLOGICAL RESEARCH, 2004, 53 (02) :123-129
12345